Discontinuation report REPATHA
Report ID | 223420 |
Drug Identification Number | 02459779 |
Brand name | REPATHA |
Common or Proper name | evolocumab injection |
Company Name | AMGEN CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | EVOLOCUMAB |
Strength(s) | 120MG |
Dosage form(s) | SOLUTION |
Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
Packaging size | 420 mg / 3.5 mL (AMD) |
ATC code | C10AX |
ATC description | LIPID MODIFYING AGENTS, PLAIN |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2024-12-31 |
Actual discontinuation date | |
Remaining supply date | 2024-12-31 |
Discontinuation status | To be discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 6775 FINANCIAL DRIVE MISSISSAUGA, ONTARIO CANADA L5N 0A4 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v10 | 2024-07-18 | French | Compare |
v9 | 2024-07-18 | English | Compare |
v8 | 2024-06-20 | French | Compare |
v7 | 2024-06-20 | English | Compare |
v6 | 2024-05-24 | French | Compare |
v5 | 2024-05-24 | English | Compare |
v4 | 2024-03-26 | French | Compare |
v3 | 2024-03-26 | English | Compare |
v2 | 2024-03-26 | French | Compare |
v1 | 2024-03-26 | English | Compare |
Showing 1 to 10 of 10